GlassScriptPhysician profile
Ronald J Sutor
NPI 1407898422
$4,618.40
in general payments reported to CMS, 2019-2025
25 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $320 · 2021: $1,384 · 2022: $694 · 2023: $444 · 2024: $213 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $677.46 | 2021-2025 | Inceptiv |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $526.77 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $356.09 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.27 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $298.18 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $255.15 | 2019-2021 | |
| Esperion Therapeutics, INC. | $231.78 | 2021 | |
| Amarin Pharma, INC. | $228.41 | 2019-2023 | |
| Medtronic Vascular, INC. | $219.56 | 2019 | |
| Novo Nordisk INC | $202.37 | 2022-2025 | Ozempic, Wegovy |
| Amgen INC. | $190.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $162.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $155.82 | 2021-2024 | Verquvo, Winrevair |
| Sanofi-Aventis U.S. LLC | $139.74 | 2019-2023 | |
| Scpharmaceuticals INC. | $115.43 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $110.20 | 2022 | |
| Incyte Corporation | $92.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $89.81 | 2022-2024 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $88.59 | 2021-2022 | |
| Atricure, INC. | $41.08 | 2023 | |
| Kestra Medical Technology Services, INC. | $33.50 | 2022-2023 | Assure Wcd |
| Edwards Lifesciences Corporation | $20.60 | 2020 | |
| Alnylam Pharmaceuticals INC. | $20.03 | 2020 | |
| Pfizer INC. | $15.66 | 2020 | |
| Irhythm Technologies, INC. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Sutor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.